DeepMed Research

IPSEN, OOO

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1929-01-01

Employees: 5.7K

Market Cap: $9.8B

Website: https://www.ipsen.com/

Clinical Trials

Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia

Phase 3

Completed

Conditions: Cervical Dystonia

Interventions: Biological: Botulinum toxin type A

First Posted Date: 2012-12-20

Last Posted Date: 2019-08-07

Lead Sponsor: Ipsen

Target Recruit Count: 112

Registration Number: NCT01753336

Locations: 🇺🇸
NeuroTrials Research Inc., Atlanta, Georgia, United States
🇺🇸
Kansas City Bone & Joint Clinic, Kansas City, Kansas, United States
🇺🇸
International Clinical Research Institute, Overland Park, Kansas, United States

and more 38 locations

A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers

Phase 2

Completed

Conditions: Advanced or Metastatic Hepatocellular Cancer
Advanced or Metastatic Ovarian Cancer
Metastatic Renal Cell Cancer
Advanced or Metastatic Gastric Carcinoma

Interventions: Drug: Tasquinimod

First Posted Date: 2012-12-06

Last Posted Date: 2019-01-08

Lead Sponsor: Ipsen

Target Recruit Count: 201

Registration Number: NCT01743469

Locations: 🇧🇪
Leuven cancer institute (LKI), Herestraat, Leuven, Belgium
🇧🇪
Antwerp University Hospital, Wilrijkstraat 10, Edegem, Belgium
🇨🇦
Juravinski Cancer Centre, 699 Concession St, Hamilton, Ontario, Canada

and more 21 locations

A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy

Phase 2

Terminated

Conditions: Metastatic Castrate Resistant Prostate Cancer

Interventions: Drug: Placebo
Drug: Tasquinimod

First Posted Date: 2012-11-26

Last Posted Date: 2019-11-22

Lead Sponsor: Ipsen

Target Recruit Count: 144

Registration Number: NCT01732549

Locations: 🇫🇷
Centre Leon Berard, Lyon, France
🇭🇺
Bajcsy-Zsilinszky Kórház, Budapest, Hungary
🇭🇺
Országos Onkológia Intézet, Budapest, Hungary

and more 13 locations

Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: Triptorelin Pamoate 11.25mg

First Posted Date: 2012-10-26

Last Posted Date: 2019-12-09

Lead Sponsor: Ipsen

Target Recruit Count: 126

Registration Number: NCT01715129

Comparing Lower-concentration Dysport Treatment Targeted to the Neuromuscular Junction With Current Clinical Practice

Phase 3

Terminated

Conditions: Arm Spasticity

Interventions: Biological: Botulinum toxin type A

First Posted Date: 2012-09-10

Last Posted Date: 2022-09-27

Lead Sponsor: Ipsen

Target Recruit Count: 100

Registration Number: NCT01682148

Locations: 🇸🇪
Sahlgrenska University Hospital, Göteborg, Sweden
🇸🇪
Danderyds Hospital,, Stockholm, Sweden
🇸🇪
Östersunds Rehabilitation Center, Östersund, Sweden

and more 20 locations

IGF-1, IGFBP3, ALS Normative Ranges in Healthy Pediatric Spanish Population

Terminated

Conditions: IGF-1 Deficiency

First Posted Date: 2012-08-30

Last Posted Date: 2019-01-11

Lead Sponsor: Ipsen

Target Recruit Count: 304

Registration Number: NCT01676090

Locations: 🇪🇸
Hospital Universitari Vall d´Hebron, Barcelona, Spain
🇪🇸
Hospital de Cruces, Bilbao, Spain
🇪🇸
Hospital Universitario Nuestra Señora de Valme, Sevilla, Spain

and more 6 locations

GP Extended Action Triptorelin

Phase 4

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Decapeptyl® SR 22.5mg
Drug: Decapeptyl® SR 11.25mg; Prostap® 3 DCS 11.25mg; Zoladex® LA 10.8mg

First Posted Date: 2012-08-28

Last Posted Date: 2025-05-23

Lead Sponsor: Ipsen

Target Recruit Count: 27

Registration Number: NCT01673984

Locations: 🇬🇧
Danes Camp Surgery, Northampton, United Kingdom
🇬🇧
The Porch Surgery, Corsham, United Kingdom
🇬🇧
Waterloo Medical Centre, Blackpool, United Kingdom

and more 32 locations

Evaluation of the Effect of Psycho-oncological Intervention on Well-being of Patients With Advanced Prostate Cancer on LHRH Analogs and Their Partners. A Randomized Controlled Pilot Study.

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Other: Psychological counseling

First Posted Date: 2012-03-26

Last Posted Date: 2019-11-07

Lead Sponsor: Ipsen

Target Recruit Count: 6

Registration Number: NCT01562522

Locations: 🇳🇱
Diakonessenhuis, Utrecht, Netherlands
🇳🇱
St. Antonius Hospital, Nieuwegein, Netherlands
🇳🇱
Zuwe Hofpoort Ziekenhuis Woerden, Netherlands, Woerden, Netherlands

Treatment Patterns Among Patients With Prostate Cancer Prior to Diagnosis of a Castration-resistant State

Completed

Conditions: Prostate Cancer

First Posted Date: 2012-03-22

Last Posted Date: 2019-01-25

Lead Sponsor: Ipsen

Target Recruit Count: 407

Registration Number: NCT01560858

Locations: 🇪🇸
Private practice, La Cañada, Paterna, Valencia, Spain

One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With Macroadenoma

Completed

Conditions: Acromegaly

First Posted Date: 2011-11-15

Last Posted Date: 2019-01-11

Lead Sponsor: Ipsen

Target Recruit Count: 54

Registration Number: NCT01471405

Locations: 🇫🇷
CHU Michallon, Grenoble, France
🇫🇷
Hôpital Haut Leveque, Pessac, France
🇫🇷
Hôpital Bicêtre, Paris, France

and more 15 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy